Day 2

The Role of DEB in Vessel Patency in BTK

solaci
solaci
242
0

CarrasqueroL1415J9
Lewis Carrasquero
2012-08-09

Previous article
Renal Denervation .The Results of the Simplycity Trials; Long Term Follow Up 
Next article
Emerging Bioabsorbable Stent and Balloon Platforms: Are the days of metallic drug-eluting stents numbered? 
solaci
solaci

More articles by this author

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

Dr. Omar Tupayachi - 0
The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Dr. Andrés Rodríguez - 0
Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Dr. Juan Manuel Pérez - 0
Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk factors. Recent studies such as COMPASS and...